KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) FCF Margin (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed FCF Margin for 16 consecutive years, with 48.17% as the latest value for Q4 2025.

  • Quarterly FCF Margin fell 824.0% to 48.17% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 46.15% through Dec 2025, up 2.0% year-over-year, with the annual reading at 46.15% for FY2025, 2.0% up from the prior year.
  • FCF Margin for Q4 2025 was 48.17% at Halozyme Therapeutics, down from 48.93% in the prior quarter.
  • The five-year high for FCF Margin was 105.71% in Q3 2021, with the low at 23.0% in Q2 2024.
  • Average FCF Margin over 5 years is 49.07%, with a median of 46.44% recorded in 2025.
  • The sharpest move saw FCF Margin soared 9624bps in 2021, then plummeted -7184bps in 2022.
  • Over 5 years, FCF Margin stood at 80.93% in 2021, then crashed by -48bps to 42.17% in 2022, then grew by 6bps to 44.72% in 2023, then grew by 26bps to 56.4% in 2024, then dropped by -15bps to 48.17% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 48.17%, 48.93%, and 30.68% for Q4 2025, Q3 2025, and Q2 2025 respectively.